Skip to main content

Rheumatoid Arthritis

    Mid-Meeting Recap: Rheumatoid Arthritis

    On Saturday, November 7th, Drs. Cush and Kavanaugh discuss rheumatoid arthritis studies presented at ACR 2020 with Dr. Kathryn Dao and Dr. Jonathan Kay.

    RT @Janetbirdope: What would you use in multidrug failure RA pt from last tweet +RF nodules & keratitis failed 2 TNF
    3 years 4 months ago
    What would you use in multidrug failure RA pt from last tweet +RF nodules & keratitis failed 2 TNFi & 2 JAKi @RheumNow #ACR20 @CRASCRRheum
    RT @drdavidliew: Low-dose steroids in RA: what's the harm, right?
    (You probably know where I'm going with this)

    ESPOIR
    3 years 4 months ago
    Low-dose steroids in RA: what's the harm, right? (You probably know where I'm going with this) ESPOIR 10y data: total events, and severe infections worse with dose and time (cumulative 8.4g ≡ 5mg/d) No doubt some residual confounding, but real risk! #ACR20 ABST1998 @RheumNow https://t.co/BAQmOR1ped
    RT @Janetbirdope: What would you use next? sero+ RA new keratitis requiring prednisone and now also 20 SJC. New rheumato
    3 years 4 months ago
    What would you use next? sero+ RA new keratitis requiring prednisone and now also 20 SJC. New rheumatoid nodules. Pt has been on triple csDMARDs + Leflunomide, then 2 JAKi and 2 TNFi also with MTX each time. All Rx works for 6 months then relapse. @RheumNow @CRASCRRheum https://t.co/9cTS1tNE42
    RT @RichardPAConway: Dr Lillegraven presents a randomized open-label phase 4, non-Inferiority trial of TNFi tapering in
    3 years 4 months ago
    Dr Lillegraven presents a randomized open-label phase 4, non-Inferiority trial of TNFi tapering in RA patients in sustained remission. 63% of tapered patients flared over 12 months vs 5% of maintained. Good response to reintroduction of TNFi @rheumnow #ACR20 Abstr#2010 https://t.co/Ki7PTsetbH
    Addressing Fatigue in Rheumatoid Arthritis: Dr Eric Dein

    Dr. Eric Dein reviews abstract #1737 at the 2020 ACR Annual Meeting.

    Flu and Tofacitinib: Dr. Kathryn Dao

    Dr. Kathryn Dao reviews abstract L04 at the 2020 ACR annual meeting.

    RT @ejdein1: Abst#2000. PRIME team Medicare database study pts with new RA started on MTX higher VTE risk than HCQ (HR 2
    3 years 4 months ago
    Abst#2000. PRIME team Medicare database study pts with new RA started on MTX higher VTE risk than HCQ (HR 2.3). Unable to assess disease activity because claims database, but would imagine MTX grp more severe, driving increased VTE risk @RheumNow #ACR20 https://t.co/Z14xFTVXTp
    RT @ejdein1: 2020 #ACR20 RA guidelines were against steroid usage in RA. ESPOIR French cohort: 10 years of very low dose
    3 years 4 months ago
    2020 #ACR20 RA guidelines were against steroid usage in RA. ESPOIR French cohort: 10 years of very low dose GC show increase events (death/CVD/fracture/severe ifn) even on low doses. HR increases every year. Cum GC dose-effect esp ifn, CVD. @RheumNow #ACRBest https://t.co/7b7chCPRxm
    RT @DrMiniDey: Another great late-breaking asbtract: #HerpesZoster in patients w/ #rheumatoidarthritis taking #upadaciti
    3 years 4 months ago
    Another great late-breaking asbtract: #HerpesZoster in patients w/ #rheumatoidarthritis taking #upadacitinib #JAKinhibitor -HZ events more common in patients taking 30mg vs 15mg -HZ more common in UPA vs those taking ADA+MTX & MTX Abs#2002 #ACR20 @RheumNow https://t.co/tQ03wBueW5